Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050934 · ClinicalTrials.gov registry record · Phase 3
Pediatric Epilepsy Study
A Phase 3 study of Epilepsy and Epilepsies, Partial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 132
- Enrollment target
- 20
- Study locations
NCT00050934: Completed Phase 3 study of Epilepsy and Epilepsies, Partial, sponsored by Novartis Pharmaceuticals.
NCT00050934 is a Phase 3 study of Epilepsy and Epilepsies, Partial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 132 participants, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00050934, a Phase 3 study of Epilepsy and Epilepsies, Partial, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 132 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as add-on therapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.
Conditions Studied
Interventions
- DRUG oxcarbazepine
Study Locations (20)
California
- - Los Angeles
- - Los Angeles
- - Madera
- - Orange
New York
- - Buffalo
- - New York
- - New York
Alabama
- - Birmingham
- - Mobile
Florida
- - Miami
- - Tampa
Minnesota
- - Duluth
- - Saint Paul
Ohio
- - Akron
- - Cincinnati
Delaware
- - Wilmington
Georgia
- - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 132 participants |
| Start Date | 2002-06 |
| Est. Completion | 2004-06 |
| Phase | Phase 3 |
What the finished NCT00050934 record still lists
NCT00050934 is an interventional study that assigns participants to a tested intervention. The registered 132 participants enrollment target is mid-sized for trials with a published cap, below the 952-participant average among 160 other Epilepsy trials with a reported enrollment target (86% lower).
The record links to 2 conditions, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which oxcarbazepine is the first listed.
NCT00050934 names 20 study sites across 11 states, led by California, New York, Alabama.
Frequently Asked Questions
What is clinical trial NCT00050934 about?
NCT00050934 is a clinical study titled "Pediatric Epilepsy Study". This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as add-on therapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.
What is the current status of trial NCT00050934?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 132 participants. The study started on 2002-06. Estimated completion is 2004-06.
What conditions does trial NCT00050934 study?
This clinical trial studies the following conditions: Epilepsy, Epilepsies, Partial.
What interventions are being tested in trial NCT00050934?
The interventions under investigation include: oxcarbazepine (DRUG).
Who is sponsoring clinical trial NCT00050934?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00050934 being conducted?
This trial has 20 study locations across Alabama, California, Delaware, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00050934's enrollment target sits among peer trials
132 44th of 160 higher than 117 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
RECRUITING · Phase 3
-
Lemborexant Treatment of Insomnia Linked to Epilepsy
RECRUITING · Phase 3
-
RNS System NAUTILUS Study
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
COMPLETED · Phase 3
-
Clobazam in Patients With Lennox-Gastaut Syndrome
COMPLETED · Phase 3
-
Pediatric Epilepsy Study
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01766297 · 132 participants · Phase 2
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
- NCT04002947 · 132 participants · Phase 2
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
- NCT04128189 · 132 participants · Phase 3
Shingrix in Renal Transplant Recipients
- NCT04199780 · 132 participants · NA
Effects of tDCS Combined With CBI on Postsurgical Pain
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia